ArticleJournal of geriatric cardiology : JGC2026
Neurodegenerative biomarkers and heart failure: is there a neurodegenerative cardiomyopathy? a systematic review and meta-analysis.
Article in Journal of geriatric cardiology : JGC, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Heart failure (HF) and cognitive impairment (CI) frequently coexist. The objective of this meta-analysis was to synthesize evidence on the association between circulating biomarkers of neurodegenerative diseases and (1) the incidence of HF; (2) cognitive dysfunction in patients with HF; and (3) adverse HF outcomes. Methods: A comprehensive search of MEDLINE and EMBASE identified 17 studies assessing plasma levels of amyloid beta (Aβ), tau protein, neurofilament light chain (NfL), glial fibrillary acidic protein (GFAP), triggering receptor expressed on myeloid cells 2 (TREM2), ubiquitin C-terminal hydrolase L1 (UCHL1), and YKL-40 in relation to HF-related outcomes. Results: Elevated Aβ40 and YKL-40 levels were significantly associated with all-cause mortality in HF, with respective hazard ratios (HR) of 1.34 (95% CI: 1.01-1.79; Conclusion: Neurodegenerative biomarkers, particularly Aβ40 and YKL-40, are indicators of risk in HF populations. These data highlight the need to validate their clinical utility and elucidate shared potentially causative mechanistic pathways linking HF and neurodegenerative conditions, defining a neurodegenerative cardiomyopathy.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.